News: Portfolio 2009

CELLUMEN APPOINTS DR. JACK A. REYNOLDS TO BOARD OF DIRECTORS

(continued)

Dr. Reynolds served as an Adjunct Clinical Professor in Comparative Medicine at Yale University and is currently an Adjunct Professor in the Division of Pharmacotherapy and Experimental Therapeutics, in the School of Pharmacy at the University of North Carolina at Chapel Hill.

 

Dr. Reynolds graduated Summa Cum Laude from Washington State University and completed a fellowship in Comparative Medicine and a residency in Comparative and Experimental Pathology at the Wake Forest Bowman Gray School of Medicine in Winston-Salem, N.C. He is certified by several specialty boards and is a Fellow of the International Academy of Toxicologic Pathologists. In 2004, Dr. Reynolds received a distinguished alumnus award for Teaching and Research from Washington State University.

About Cellumen

Cellumen is the leading collaborative partner and outsource service provider for the continuum of cell-based drug discovery and discovery toxicology solutions. Through its CellCiphr® CSB™ Toxicity Profiling Services, Cellumen can predict the safest, most effective drugs in the drug discovery process, and as a result, reduce drug failure rates and cut development costs. Leading global organizations, including top pharmaceutical companies, the EPA, FDA, and NIH, partner with Cellumen. Cellumen is a partner company of Safeguard Scientifics. Other investors include Novitas Capital, the Pittsburgh Life Sciences Greenhouse and Innovation Works. For more information about Cellumen, please visit www.cellumen.com.

 

 
Cellumen Media Contact
Theresa Murray
Gregory FCA
610-642-8253 x164
Theresa@GregoryFCA.com

Page: 1 2